MONTREAL, CANADA--(Marketwire - Nov. 24, 2011) - Theratechnologies Inc. (TSX:TH)(NASDAQ:THER) was presented with the prestigious Product Innovation Award for its lead compound, tesamorelin, at the 21th Quebec Association of Industrial Research (ADRIQ) Innovation Awards Gala held on November 22, 2011.

"Theratechnologies is one of the few biotechs in Quebec that has managed to successfully gain FDA approval for a product and we are very proud to be recognized by ADRIQ," stated Mr. John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies.

Tesamorelin, marketed in the U.S. as EGRIFTA® for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, is a growth-hormone releasing factor discovered and developed by Theratechnologies in Quebec. It was approved in November 2010 by the U.S. Food and Drug Administration (FDA) and launched in the U.S. by a commercial partner in January 2011. Applications for tesamorelin are also currently under review with regulatory agencies in Canada, Europe, Latin America and the Middle East.

Founded in 1996, the Quebec Association of Industrial Research (ADRIQ) Product Innovation Award recognizes Quebec companies that have recently distinguished themselves by developing and marketing an innovative product, contributing to the company's growth in their respective markets.

About Theratechnologies

Theratechnologies (TSX:TH)(NASDAQ:THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at Additional information, including the Annual Information Form and the Annual Report, is also available on SEDAR at and on the Securities and Exchange Commission's website at

Contact Information:

Serge Vallieres
NATIONAL Public Relations